Monitor for Personalis shareholder vote and HSR regulatory clearance as key milestones toward Q4 2026 close. The stock-for-stock structure means TEM's stock price at closing will determine the final exchange ratio; a decline below $46.00 gives Personalis the right to terminate. Watch for any competing bids or activist interest given the modest 6% premium to Personalis's closing price.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 21 $48.98entry
- T+1 · 4mo ago −4.12%α −4.01% · $46.96
- T+5 · 4mo ago −12.39%α −11.16% · $42.91
- T+20 · 3mo ago +0.78%α −1.79% · $49.36
- T+60 · 5w ago +39.28%α +35.31% · $68.22
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tempus AI (TEM) filed an investor presentation deck as a Rule 425 communication, reinforcing its July 20, 2026 announcement to acquire Personalis (PSNL) for $16.25/share in a stock-for-stock transaction valued at $1.7Bn ($1.5Bn net of Tempus's existing stake). The presentation emphasizes the strategic rationale of integrating Personalis's ultrasensitive MRD technology into Tempus's AI-enabled precision oncology platform, targeting a >$20B market opportunity, and highlights Personalis's Q2 test volume of 10,384 (33% sequential growth) and >35,000 total tests delivered. The deal is expected to close in Q4 2026, subject to Personalis shareholder approval and regulatory clearances.
Key Financial Metrics
Key Facts
- Total transaction value of $1.7Bn ($1.5Bn net of Tempus's existing ownership interest)
- Personalis shareholders to receive $16.25 per share in a combination of Tempus stock and up to 50% cash at Tempus's discretion
- Floating exchange ratio with a maximum of 0.3356x Tempus Class A common stock per Personalis share
- Closing expected in Q4 2026 at earliest, subject to Personalis shareholder approval and regulatory clearances (including HSR)
- Personalis has delivered >35,000 tests to date, with Q2 sequential test volume growth of 33% (10,384 tests in Q2)
- Only ~10% of Tempus's sales force currently sells NeXT Personal Dx, implying significant volume acceleration potential
- Tempus's infrastructure includes ~65% of U.S. academic medical centers and >55% of oncologists connected, with ~1M NGS tests run annually across 4 labs
Financial Impact
Acquisition valued at $1.7Bn total ($1.5Bn net of existing stake), representing ~18% of Tempus's $9.4B market cap. The deal expands Tempus into a >$20B MRD market and is expected to drive meaningful revenue growth through full ownership of Personalis's test portfolio and commercial infrastructure.
Risk Factors
- Integration risk combining two platforms and sales forces
- Regulatory approval delays or conditions (HSR clearance)
- Personalis shareholder approval not obtained
- Termination risk if Tempus stock falls below $46.00 prior to closing
- Potential litigation challenging the transaction
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (TEM), Batch item 1 | 0001193125-26-309090 |
| Document: 0001193125-26-309090-index-headers.html | 0001193125-26-309090 |
| Document: 0001193125-26-309090-index.html | 0001193125-26-309090 |
| Document: 0001193125-26-309090.txt | 0001193125-26-309090 |
| 425 Filing (TEM), Batch item 5 | 0001193125-26-309090 |
Track record
45 reports on TEM
7 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +53.09% at T+60 after the Jul 30, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 9, 20267d ago Press Release Neutral 3/10 Entry $80.54 Now $64.76 −19.59% settles Feb 8
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $76.05 Now $64.76 −14.85% settles Feb 4
- Nov 4, 202612d ago Insider Cluster Neutral 3/10 Entry $70.43 Now $64.76 −8.05% settles Feb 3
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $77.80 Now $64.76 −16.76% settles Feb 1
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $78.48 Now $64.76 −17.48% settles Jan 29
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $77.84 Now $64.76 −16.80% settles Jan 27
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $76.61 Now $64.76 −15.47% settles Jan 26
- Oct 27, 202620d ago 144 Neutral 3/10 Entry $76.61 Now $64.76 −15.47% settles Jan 26
- Oct 23, 202624d ago 8-K Bullish 6/10 Entry $67.62 Now $64.76 −4.22% settles Jan 21
- Oct 22, 202626d ago EFFECT Neutral 4/10 Entry $63.81 Now $64.76 +1.49% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers